RKLB Rocket Lab Corp Insider Trading

Director Alexander Slusky sold 60,000 RKLB shares ($8,964,092.00) at $149.10–$150.00; stock now at $122.39 (-19.0% from 52-wk high).

Alexander R Slusky, a Director at Rocket Lab, executed 2 separate sales totaling 60,000 shares for $8,964,092.00 at prices of $149.10 and $150.00 on 2026-05-28, reducing his holdings by 13.8% to 374,675 shares. The sales occurred near the 52-week high of $151.00; the current price of $122.39 is now 19.0% below that peak, and the stock has gained 55.3% over the 30 days since the transaction but fallen from the transaction prices. Slusky's prior trades at this ticker show poor 90-day timing (1 of 5 prior sells were well-timed), and his cross-ticker track record shows average 90-day returns of +8.5% following his sells, indicating he has historically sold before rallies rather than before declines. The company's fundamentals remain under pressure: it reported negative net income of $-45,022,000.00 on quarterly revenue of $200,348,000.00 despite 38.0% annual revenue growth, and remains unprofitable on a full-year basis. The timing and size of this director sale warrant attention given the proximity to the 52-week high and the company's ongoing unprofitability.

COO Frank Klein sells 36,860 shares at blended avg $147.42 under pre-arranged 10b5-1 plan; stock now $122.39.

Frank Klein, COO of Rocket Lab, executed 8 separate sales totaling 36,860 shares for $5,433,997.64 on 2026-05-28 under a 10b5-1 trading plan adopted 2025-09-19, reducing his holdings by 3.5% to 1,006,987 shares. The transactions were spread across prices from $143.05 to $149.99, with a blended average of $147.42. The current stock price of $122.39 represents a 19.0% decline from the 52-week high of $151.00, placing the sale prices near the recent peak of the stock's range. As a scheduled transaction under a pre-arranged plan, this sale carries no timing implication; however, the fact that prior sales by this insider at RKLB on 2026-03-04 showed negative 30-day returns (-3.6% to -8.2%) while producing strong 90-day gains (+103.5% to +113.8%) suggests a historical pattern where this ticker has recovered significantly after near-term declines. The company remains unprofitable on a full-year basis with net income of $-45,022,000.00, though quarterly revenue reached $200,348,000.00 with annual growth of +38.0%.

Rocket Lab President Marvin Clevenger sold 3,500 shares at $146.67 on 2026-05-28 (total: $513,355.85), reducing stake to 474.0K shares.

Marvin Bradford Clevenger, President of Rocket Lab USA, Inc, executed a modest sale of 3,500 shares (3.5K shares) representing -0.7% of his pre-transaction holdings, at a price of $146.67 per share. The sale occurred when the stock stood 19.0% below its 52-week high of $151.00, despite strong recent momentum (30-day change: +55.3%, 90-day change: +74.5%). While the company remains unprofitable with a full-year net income of $-45.0M, it has achieved robust annual revenue growth of +38.0%, reaching $200.3M in the latest quarter. The magnitude and proportion of this sale are limited relative to Clevenger's remaining holdings of 473,975 shares (474.0K shares), and the absolute transaction size of $513,355.85 does not suggest a material shift in position.

SVP & General Counsel sold 23,804 shares at blended avg $147.43 on 2026-05-28 (scheduled 10b5-1 plan), stock now -19.0% from 52-week high

Arjun Kampani executed 8 separate sales totaling 23,804 shares for $3,509,510.74 on 2026-05-28 at prices ranging from $143.15 to $150.26, reducing his holdings by 6.3%. This transaction was part of a pre-arranged 10b5-1 trading plan adopted on 2025-09-19, meaning the sales were scheduled rather than discretionary timing decisions. The stock has since declined to $122.39, trading 19.0% below its 52-week high of $151.00. Notably, his prior trades at RKLB (5 sales in March 2026) showed negative 30-day returns (ranging from -4.0% to -8.6%) followed by substantial 90-day gains (102.8% to 113.0%), a pattern that does not appear in his cross-ticker track record where the average 90-day return after 20 prior sells was +72.2%. The company is currently unprofitable with net income of $-45,022,000.00 against revenue of $200,348,000.00, though it achieved annual revenue growth of +38.0%.

CFO Adam C. Spice sold 62,744 shares for $8,945,631.27 via scheduled 10b5-1 plan on 2026-05-26.

Adam C. Spice, CFO of Rocket Lab Corp, executed 6 separate sales totaling 62,744 shares for $8,945,631.27 on 2026-05-26 at prices ranging from $139.41 to $144.13, reducing his holdings from 1,045,793 shares to 983,049 shares (-6.0%). The transaction is part of a pre-arranged 10b5-1 trading plan, meaning it was scheduled rather than discretionary. At the time of sale, the stock was trading near its 52-week high of $151.00 (current price $148.03, -2.0% from peak), and the company's 90-day return stands at +114.2%, though the company remains unprofitable with negative net income of $-45,022,000.00 on revenue of $200,348,000.00. His prior sales at RKLB (5 trades on 2026-03-02) showed mixed 30-day results ranging from -7.2% to -2.0%, though 90-day results were consistently positive, ranging from +112.7% to +124.8%.

COO Frank Klein sells 44,390 shares at blended avg $142.57 for $6.3M via scheduled 10b5-1 plan

Frank Klein, Chief Operations Officer, executed 6 separate sales totaling 44,390 shares for $6,328,838.37 on 2026-05-26 via a pre-arranged 10b5-1 trading plan—a scheduled transaction not reflective of discretionary decision-making. This sale reduces his holdings from 1,088,237 shares to 1,043,847 shares, a -4.1% change. The broader context is notable: Rocket Lab's stock is currently at $148.03, up +88.4% over 30 days and +114.2% over 90 days, while the company posted $200,348,000.00 in latest-quarter revenue but remains unprofitable with full-year net income of $-45,022,000.00. Klein's 5 prior trades at RKLB (all on 2026-03-04) each generated positive 90-day returns ranging from +103.5% to +113.8%, a pattern consistent with his cross-ticker track record showing average 90-day return of +57.8% after prior sales. Because this sale occurs via a preset 10b5-1 plan rather than a discretionary choice, the transaction itself carries limited signal about Klein's current conviction on the stock or business trajectory.

SVP & General Counsel Arjun Kampani sold 98,668 shares for $14.2M on 2026-05-26/27 per 10b5-1 plan.

Arjun Kampani executed 8 separate sales totaling 98,668 shares (98.7K shares) for $14,246,080.47 ($14.2M) on 2026-05-26 and 2026-05-27 under a pre-arranged 10b5-1 trading plan. Transaction prices ranged from $139.41 to $150.00, with a blended average of $144.38, compared to a current price of $148.03. The sales reduced his holdings by 20.8% (from 475.2K to 376.5K shares). Because this transaction is part of a scheduled 10b5-1 plan rather than discretionary action, the timing reflects a pre-established schedule rather than an active investment decision. His prior 5 trades at this ticker (all on 2026-03-04) showed negative 30-day returns ranging from -4.0% to -8.6%, though all posted positive 90-day returns (+102.8% to +113.0%). The company is currently unprofitable (net income $-45.0M most recent quarter) despite strong revenue growth of +38.0% year-over-year and a substantial market cap of $85.7B.

Rocket Lab President Clevenger sold 15,549 shares for $2.2M at blended price of $142.57, retaining 477,475 shares post-sale.

Marvin Bradford Clevenger, President of Rocket Lab USA, Inc, executed 6 separate sales on 2026-05-26 totaling 15,549 shares for $2,216,875.19, with prices ranging from $139.41 to $144.13 and a blended average of $142.57. The sale reduced his holdings by 3.2% to 477,475 shares. This disposal occurs in a context of substantial recent stock appreciation: the stock has risen 88.4% over the past 30 days and 114.2% over 90 days, currently trading at $148.03 (near its 52-week high of $151.00). The company itself remains unprofitable on a full-year basis with net income of $-45,022,000.00 against quarterly revenue of $200,348,000.00, though it shows strong annual revenue growth of 38.0%. The multiple transactions at incrementally rising prices reflect a systematic execution pattern rather than a single decision point.

RKLB Director Slusky sells 100.0K shares for $11.8M near 52-week high; stock up +83.5% in 30 days

Director Slusky Alexander R sold 100,000 shares of Rocket Lab Corp (RKLB) for $11.8M across multiple transactions on 2026-05-12, with sale prices ranging from $115.05 to $120.01, while the current price sits at $132.55 — +4.2% above the 52-week high of $127.24 following a +83.5% surge in the past 30 days. This sale represents a meaningful reduction from a still-substantial post-transaction holding of 434.7K shares. His cross-ticker track record shows a 90-day well-timed rate of 100.00% across 2 prior sells, and his 2 prior trades specifically at RKLB — both sells in December 2024 — showed subsequent 90-day declines of -18.9% and -15.6%, reinforcing a pattern of well-timed exits at this ticker. Rocket Lab remains unprofitable with net income of $-45,022,000.00 on latest-quarter revenue of $200.3M, meaning the stock's $76.7B market cap rests heavily on growth expectations, making this large insider sale during an extended momentum run a signal worth monitoring.